双氯芬酸钠眼部给药：使用人角膜构建体对新型固体脂质纳米粒制剂进行体外评价

Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct.

作者信息

Attama Anthony A, Reichl Stephan, Müller-Goymann Christel C

机构信息

Institut für Pharmazeutische Technologie, Technische Universität Carolo-Wilhelmina zu Braunschweig, Mendelssohnstrasse 1, D-38106 Braunschweig, Germany.

出版信息

Int J Pharm. 2008 May 1;355(1-2):307-13. doi: 10.1016/j.ijpharm.2007.12.007. Epub 2007 Dec 17.

DOI:10.1016/j.ijpharm.2007.12.007

PMID:18242022

Abstract

Solid lipid nanoparticles (SLNs) were prepared with a combination of homolipid from goat (goat fat) and phospholipid, and evaluated for diclofenac sodium (DNa) delivery to the eye using bio-engineered human cornea, produced from immortalized human corneal endothelial cells (HENC), stromal fibroblasts and epithelial cells CEPI 17 CL 4. Encapsulation efficiency was high and sustained release of DNa and high permeation through the bio-engineered cornea were achieved. Results obtained in this work showed that permeation of DNa through the cornea construct was improved by formulation as SLN modified with phospholipid.

摘要

采用山羊来源的单一脂质（羊脂）与磷脂组合制备了固体脂质纳米粒（SLNs），并使用由永生化人角膜内皮细胞（HENC）、基质成纤维细胞和上皮细胞CEPI 17 CL 4构建的生物工程化人角膜，评估其用于双氯芬酸钠（DNa）眼部给药的效果。实现了高包封率以及DNa的持续释放和通过生物工程化角膜的高渗透率。本研究获得的结果表明，通过用磷脂修饰的SLN制剂可提高DNa透过角膜构建体的渗透率。